Upstream Processing

Articles

Mogrify’s new technology platform, EpiMOGRIFY, can predict cellular switches important for determining cell identity, cell maintenance, directed differentiation, and cell conversion.

New EpiMOGRIFY Technology Platform Offers Development Support for Allogeneic Cell Therapies

The new VirusExpress lentiviral production platform increases dose yields and reduces process development time for cell and gene therapies.

MilliporeSigma Launches Lentiviral Production Platform for Cell and Gene Therapies

Melisa Carpio is a global technology consultant for Cell Culture Technologies at Sartorius North America.

Bioreactor technology advances can offer seamless manufacturing scale-up and can reduce the timeline and cost of biologics production.

Current Challenges with Cell Culture Scale-up for Biologics Production 

The investment will include new manufacturing lines and increased automation to deliver additional manufacturing capacity.

Cytiva Invests $500 Million Over 5 years to Expand Global Capacity

The company has made several moves in recent weeks to expand manufacturing capacity and cell line services.

Samsung Biologics Expands Manufacturing Facilities and Launches Cell Line Technology

Innovative approaches, including ready-to-use materials and in-line dilution, can significantly streamline overall bioprocessing operations.

Improving mAb Manufacturing Productivity by Optimizing Buffer and Media Prep Process Flow

Advanced data analytics, including statistical modeling and machine learning technique, can enable more efficient and reliable bioprocesses.

Understanding Commercial Cell Culture Process Performance Variation Through Advanced Data Analytics

Agnes Shanley is senior editor of Pharmaceutical Technology.

Better understanding and control of cell behavior is yielding benefits, upstream and beyond. 


Improving Upstream Predictability

Feliza Mirasol is the science editor for 

The future of raw material sourcing for mAb production may lay in the sustainability of the source and the added benefits of newer technologies.


The Future of Raw Material Sources for mAbs

The production of viral vectors for use in gene therapy benefits from being able to use similar cell-culture processes as mAbs, but it faces limitations under current cell-culture technologies.

Manufacturing, Cell Culture and Fermentation